Sun Pharma Advanced Research Company Limited (Sparc) (NSE: SPARC, BSE: 532872) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹6,834 Cr, it ranks #724 by market cap among the 6,197 Indian listed companies on FinBizNet, and #15 of 63 in Pharmaceuticals. At ₹206.50 (as of 16 Nov 2026), the share price is 28.5% below its 52-week high of ₹289.00 and 91.2% above its 52-week low of ₹108.00. The share price is up 54.4% over one year and up 0.8% over three months.
| Current Price | ₹206.50 |
|---|---|
| Market Cap | ₹6,834 Cr |
| NSE Symbol | SPARC |
| BSE Code | 532872 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 4.4 |
| Return on Equity | 2.77% |
| Return on Assets | 79.74% |
| 52-Week Range | ₹108.00 – ₹289.00 |
| 1-Year Price Change | +54.4% |
| 3-Month Price Change | +0.8% |
| Beta (1Y) | 0.82 |
| Headquarters | Mumbai, Maharashtra |
| Website | sparc.life |
| Revenue | ₹30 Cr |
|---|---|
| Net Profit | ₹-24 Cr |
| Net Margin | -81.2% |
| EPS (Basic) | ₹-0.75 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Sun Pharma Advanced Research Company Limited (Sparc) reported revenue of ₹30 Cr in Q2 FY27, up 282.1% from ₹8 Cr in Q2 FY26 and down 24.8% from ₹40 Cr in Q1 FY27. It posted a net loss of ₹24 Cr for the quarter, against a net loss of ₹76 Cr in Q2 FY26. Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹8 Cr (Q2 FY26) to ₹1,853 Cr (Q4 FY26). The company reported a net loss in 6 of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹30 Cr | −₹24 Cr | −81.2% |
| Q1 FY27 | ₹40 Cr | −₹21 Cr | −52.1% |
| Q4 FY26 | ₹1,853 Cr | ₹1,761 Cr | 95.0% |
| Q3 FY26 | ₹8 Cr | −₹80 Cr | −951.7% |
| Q2 FY26 | ₹8 Cr | −₹76 Cr | −965.0% |
| Q1 FY26 | ₹10 Cr | −₹52 Cr | −538.1% |
| Q4 FY25 | ₹27 Cr | −₹60 Cr | −219.8% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 65.67% of Sun Pharma Advanced Research Company Limited (Sparc)'s shares as of Sept 2026, unchanged from Dec 2025. Delivery averaged 33.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.
1. Pharmaceuticals Research and Development-This segment engages in the research and development of pharmaceutical products.
1. Pharmaceuticals Research and Development-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Sun Pharma Advanced Research Company Limited (Sparc) | ₹6,834 Cr | 4.4 | 2.77% | ₹30 Cr | +54.4% |
Listed by market capitalisation. Ratios are shown for context only.
Sun Pharma Advanced Research Company Limited (Sparc) is trading at ₹206.50, with a market capitalisation of ₹6,834 Cr.
Sun Pharma Advanced Research Company Limited (Sparc) operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Sun Pharma Advanced Research Company Limited (Sparc) has a P/E of 4.4 and a return on equity of 2.77%.
Sun Pharma Advanced Research Company Limited (Sparc) is listed on the NSE under the symbol SPARC and on the BSE under the scrip code 532872.
Sun Pharma Advanced Research Company Limited (Sparc)'s share price is up 54.4% over one year and up 0.8% over three months. Its 52-week range is ₹108.00 to ₹289.00.
In Q2 FY27, Sun Pharma Advanced Research Company Limited (Sparc) reported revenue of ₹30 Cr and net profit of ₹-24 Cr, with basic EPS of ₹-0.75 (consolidated, parsed from the company's exchange filing).
Sun Pharma Advanced Research Company Limited (Sparc) reported revenue of ₹30 Cr in Q2 FY27, up 282.1% from ₹8 Cr in Q2 FY26 and down 24.8% from ₹40 Cr in Q1 FY27.
Promoters held 65.67% of Sun Pharma Advanced Research Company Limited (Sparc)'s shares as of Sept 2026, unchanged from Dec 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.